Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label trial of human cytomegalovirus intravenous immunoglobulin (pH4) plus antivirals after allogeneic HSCT
ChiCTR1800014783Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2018
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of human cytomegalovirus intravenous immunoglobulin (pH4) in cytomegalovirus disease (CMV) (3 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Percentage of patients with CMV-DNA below 1000 copies/mL on two consecutive tests within 2 weeks after treatment initiation. Started Jan 2018; status: recruiting.
02
Drugs
human cytomegalovirus intravenous immunoglobulin (pH4)
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on ChiCTR1800014783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014783.